# Advanced Therapy Medicinal Products Cdmo Market > Advanced Therapy Medicinal Products CDMO Market Research Report By Product Type (Gene Therapy, Cell Therapy, Tissue Engineering), By Indication (Cancer, Immune Disorders, Cardiovascular Diseases, Neurological Disorders), By Scale of Production (Clinical Trial, Commercial Production), By Service Type (Process Development, Manufacturing, Regulatory Support) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 14.64% - **2024:** $ 29.97 Billion - **2025:** $ 34.36 Billion - **2035:** $ 134.73 Billion - **Key Players:** Lonza (CH), Catalent (US), Samsung Biologics (KR), WuXi AppTec (CN), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), AptarGroup (US), Novartis (CH), Thermo Fisher Scientific(US) **Report ID:** MRFR/HC/29380-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/advanced-therapy-medicinal-products-cdmo-market-31150 --- ## Market Summary ## **Advanced Therapy Medicinal Products CDMO Market Overview** As per MRFR analysis, the Advanced Therapy Medicinal Products CDMO Market Size was estimated at 29.97 (USD Billion) in 2024. The Advanced Therapy Medicinal Products CDMO Market Industry is expected to grow from 34.36 (USD Billion) in 2025 to 117.52 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 14.64% during the forecast period (2025 - 2034). ### **Key Advanced Therapy Medicinal Products CDMO Market Trends Highlighted** The Advanced Therapy Medicinal Products (ATMPs) CDMO market is seeing rapid growth, driven by the rising prevalence of chronic diseases and the increasing demand for personalized medicine. Key market drivers include advancements in gene therapy, cell therapy, and tissue engineering, which are creating new opportunities for the development of ATMPs. Additionally, government initiatives and favorable regulatory environments are further fueling market growth. Recent trends in the ATMP CDMO market include the adoption of innovative technologies such as artificial intelligence (AI) and machine learning (ML) to improve efficiency and precision in manufacturing processes. The market is also witnessing a shift towards integrated CDMO services, where providers offer a comprehensive range of services from early-stage development to commercial manufacturing. Moreover, there is a growing focus on patient-centricity, with CDMOs prioritizing the delivery of high-quality, personalized therapies. Opportunities for exploration in the ATMP CDMO market lie in the development of new ATMPs for unmet medical needs, the expansion into emerging markets, and the adoption of novel technologies. By leveraging these opportunities, CDMOs can position themselves for continued growth and success in this dynamic market. **Source: Primary Research, Secondary Research, MRFR Database and Analyst Review** ## **Advanced Therapy Medicinal Products CDMO Market Drivers** ### **Increasing Prevalence of Chronic Diseases** The rising incidence of chronic diseases, such as cancer, cardiovascular diseases, and neurodegenerative disorders, is a major driver of the global advanced therapy medicinal products CDMO market. Advanced therapies, including gene therapies, cell therapies, and tissue engineering, offer promising treatment options for these debilitating conditions, leading to increased demand for CDMO services to support the development and manufacturing of these therapies. The ability of advanced therapies to target specific genetic defects or disease mechanisms has opened up new avenues for personalized medicine, further fueling the growth of the CDMO market. Moreover, the increasing prevalence of rare diseases for which traditional treatments may be ineffective is also contributing to the demand for advanced therapies and the associated CDMO services. ### **Technological Advancements and Innovation** The rapid pace of technological advancements in the field of biotechnology is another key driver of the global advanced therapy medicinal products CDMO market. The development of novel gene editing techniques, such as CRISPR-Cas9, and advancements in cell culture and manufacturing technologies have significantly improved the efficiency and precision of advanced therapy development. These technological advancements have enabled the creation of more effective and targeted therapies, leading to increased demand for CDMO services to support the scale-up and commercialization of these products. Furthermore, ongoing research and development efforts in the field of regenerative medicine and tissue engineering hold immense promise for the treatment of a wide range of diseases and injuries, further driving the growth of the CDMO market. ### **Government Support and Regulatory Landscape** Government support and favorable regulatory policies play a crucial role in fostering the growth of the global advanced therapy medicinal products CDMO market. Governments worldwide recognize the potential of advanced therapies to transform healthcare and improve patient outcomes. As a result, many countries have implemented supportive policies, including funding for research and development, tax incentives for companies investing in this field, and streamlined regulatory pathways for the approval of advanced therapies. These measures have created a conducive environment for the development and commercialization of advanced therapies, leading to increased demand for CDMO services to support the manufacturing and clinical trials of these products. ## **Advanced Therapy Medicinal Products CDMO Market Segment Insights** ### **Advanced Therapy Medicinal Products CDMO Market Product Type Insights** The Advanced Therapy Medicinal Products CDMO Market is segmented by product type into [gene therapy](../../../reports/gene-therapy-market-8399), cell therapy, and tissue engineering. Gene therapy involves modifying a patient's genes to treat or prevent a disease. Cell therapy involves using cells to repair or replace damaged tissues or organs. Tissue engineering involves creating new tissues or organs from cells or other materials. The Advanced Therapy Medicinal Products CDMO Market revenue for gene therapy is expected to grow from USD 2.5 billion in 2023 to USD 10.5 billion by 2030, at a CAGR of 22.5%. The growth of the gene therapy segment is attributed to the increasing prevalence of genetic disorders and the development of new gene therapies. The Advanced Therapy Medicinal Products CDMO Market revenue for cell therapy is expected to grow from USD 5.0 billion in 2023 to USD 20.0 billion by 2030, at a CAGR of 25.0%. The growth of the cell therapy segment is attributed to the increasing demand for cell-based therapies for the treatment of cancer and other diseases. The Advanced Therapy Medicinal Products CDMO Market revenue for tissue engineering is expected to grow from USD 3.0 billion in 2023 to USD 12.0 billion by 2030, at a CAGR of 20.0%. The growth of the tissue engineering segment is attributed to the increasing demand for tissue-engineered products for the repair and replacement of damaged tissues and organs. **Source: Primary Research, Secondary Research, MRFR Database and Analyst Review** ### **Advanced Therapy Medicinal Products CDMO Market Indication Insights ** The Advanced Therapy Medicinal Products CDMO Market is segmented by indication, which includes cancer, immune disorders, cardiovascular diseases, and neurological disorders. Among these, cancer holds the largest market share due to the increasing prevalence of various types of cancer and the growing demand for personalized and targeted therapies. The Advanced Therapy Medicinal Products CDMO Market for Cancer is expected to reach USD 35.2 billion by 2024, growing at a CAGR of 15.2%. The market for immune disorders is also expected to witness significant growth, driven by the rising incidence of autoimmune diseases and the development of novel immunotherapies. The cardiovascular diseases segment is expected to grow at a steady pace, supported by the increasing prevalence of cardiovascular diseases and the growing adoption of advanced therapies for the treatment of these diseases. The neurological disorders segment is also expected to experience growth, driven by the increasing prevalence of neurological disorders and the growing demand for advanced therapies for the treatment of these disorders. ### **Advanced Therapy Medicinal Products CDMO Market Scale of Production Insights** The Scale of Production segment plays a crucial role in the global advanced therapy medicinal products CDMO market. It is categorized into two primary sub-segments: Clinical Trial and Commercial Production. The Clinical Trial sub-segment held a significant share of the market in 2023, primarily driven by the increasing number of clinical trials for advanced therapies. As per market data, the Clinical Trial sub-segment is projected to reach a valuation of approximately 6.5 billion USD by 2032, exhibiting a robust CAGR of 13.2%. The Commercial Production sub-segment is anticipated to witness substantial growth in the coming years, owing to the growing demand for commercial manufacturing of advanced therapies. Industry statistics indicate that the Commercial Production sub-segment is expected to reach a valuation of around 5.8 billion USD by 2032, expanding at a CAGR of 14.9%. This growth is attributed to the increasing prevalence of chronic diseases and the rising adoption of advanced therapies as treatment options. ### **Advanced Therapy Medicinal Products CDMO Market Service Type Insights** The Advanced Therapy Medicinal Products CDMO Market is segmented into service type, which includes process development, manufacturing, and regulatory support. The manufacturing segment is expected to hold the largest share of the market in 2023, with a valuation of 11.87 billion USD. This is due to the increasing demand for contract manufacturing services for advanced therapy medicinal products (ATMPs) as companies look to outsource their manufacturing processes to specialized providers. The process development segment is expected to grow at the highest CAGR of 15.24% over the forecast period, as companies invest in developing new and innovative ATMPs. Regulatory support is another important segment of the market, as companies require assistance in navigating the complex regulatory landscape for ATMPs. ### **Advanced Therapy Medicinal Products CDMO Market Regional Insights** The Advanced Therapy Medicinal Products CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. The growth of the North American market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a large number of pharmaceutical and biotechnology companies in the region. Europe is expected to be the second-largest market for advanced therapy medicinal products CDMO in 2023 and is projected to grow at a steady pace during the forecast period. The growth of the European market is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of leading pharmaceutical and biotechnology companies in the region. The APAC market is expected to be the fastest-growing regional market for advanced therapy medicinal products CDMO during the forecast period. The growth of the APAC market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region. South America and MEA are expected to be relatively smaller markets for advanced therapy medicinal products CDMO but are projected to grow at a steady pace during the forecast period. The growth of these markets is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region. **Source: Primary Research, Secondary Research, MRFR Database and Analyst Review** ## **Advanced Therapy Medicinal Products CDMO Market Key Players and Competitive Insights** Major players in the advanced therapy medicinal products CDMO market are focusing on developing innovative technologies and expanding their global presence through strategic partnerships and acquisitions. Leading advanced therapy medicinal products CDMO market players are investing heavily in research and development to enhance their product portfolio and gain a competitive edge. The advanced therapy medicinal products CDMO market development is driven by rising demand for personalized medicine and increasing government support for regenerative therapies. The competitive landscape is expected to remain fragmented, with several key players holding significant market share. Lonza is a leading provider of Advanced Therapy Medicinal Products CDMO Market services, offering a comprehensive range of solutions for cell and gene therapies, including cell culture media, bioprocess development, and manufacturing. The company has a strong global presence with facilities in Europe, North America, and Asia. Lonza's commitment to innovation and customer service has earned it a reputation as a trusted partner for biotechnology and pharmaceutical companies. Samsung Biologics is another major player in the advanced therapy medicinal products CDMO market. The company offers a full suite of services for cell and gene therapy development and manufacturing, including cell line development, process optimization, and GMP manufacturing. Samsung Biologics has a state-of-the-art manufacturing facility in South Korea and is expanding its global presence through partnerships with leading biotechnology companies. ### **Key Companies in the advanced therapy medicinal products CDMO market Include** - MeiraGTx - Wuxi Advanced Therapies - Bristol-Myers Squibb - **[Thermo Fisher Scientific](https://www.thermofisher.com/in/en/home/products-and-services/services/crdmo.html)** - Catalent - Amgen - Biogen - AAV gene therapy - Pfizer - Fujifilm - Samsung Biologics - Cellectis - Lonza - Wuxi AppTec ## Advanced Therapy Medicinal Products Cdmo Market Developments - **Q2 2024: Catalent opens new cell therapy manufacturing facility in Belgium** Catalent announced the opening of a new commercial-scale cell therapy manufacturing facility in Gosselies, Belgium, expanding its advanced therapy medicinal product (ATMP) CDMO capabilities in Europe. - **Q2 2024: Charles River Laboratories and Cellarity Announce Strategic Partnership to Advance Cell Therapy Manufacturing** Charles River Laboratories and Cellarity entered a strategic partnership to accelerate the development and manufacturing of cell therapies, leveraging Charles River’s CDMO expertise for advanced therapy medicinal products. - **Q2 2024: WuXi Advanced Therapies Expands Philadelphia Facility to Boost Cell and Gene Therapy Manufacturing** WuXi Advanced Therapies completed a major expansion of its Philadelphia facility, increasing capacity for cell and gene therapy manufacturing services as a CDMO for advanced therapy medicinal products. - **Q2 2024: Minaris Regenerative Medicine Announces New Commercial Manufacturing Agreement with Autolus Therapeutics** Minaris Regenerative Medicine signed a commercial manufacturing agreement with Autolus Therapeutics to provide CDMO services for the production of Autolus’ advanced cell therapy products. - **Q1 2024: Lonza Expands Cell and Gene Therapy Manufacturing Capabilities with New Suite in Houston** Lonza announced the opening of a new manufacturing suite at its Houston facility, enhancing its capacity to deliver CDMO services for advanced therapy medicinal products. - **Q1 2024: Samsung Biologics to Acquire Stake in Gene Therapy CDMO Senda Biosciences** Samsung Biologics agreed to acquire a minority stake in Senda Biosciences, a CDMO specializing in gene therapy, to expand its advanced therapy medicinal product service portfolio. - **Q2 2024: Thermo Fisher Scientific Launches New Plasmid DNA Manufacturing Facility in California** Thermo Fisher Scientific opened a new plasmid DNA manufacturing facility in Carlsbad, California, to support the growing demand for CDMO services in the advanced therapy medicinal products sector. - **Q2 2024: AGC Biologics Announces Partnership with Adaptimmune for Cell Therapy Manufacturing** AGC Biologics entered a partnership with Adaptimmune to provide contract manufacturing services for Adaptimmune’s cell therapy pipeline, expanding AGC’s advanced therapy medicinal product CDMO offerings. - **Q1 2024: CellPoint and Lonza Enter Manufacturing Collaboration for Point-of-Care CAR-T Therapies** CellPoint and Lonza announced a collaboration to develop and manufacture point-of-care CAR-T cell therapies, leveraging Lonza’s CDMO expertise in advanced therapy medicinal products. - **Q2 2024: VIVEbiotech Expands Lentiviral Vector Manufacturing Facility in Spain** VIVEbiotech completed an expansion of its lentiviral vector manufacturing facility in San Sebastián, Spain, to meet increased demand for CDMO services in the advanced therapy medicinal products market. - **Q1 2024: Cellares Raises $255 Million Series C to Scale Automated Cell Therapy Manufacturing** Cellares secured $255 million in Series C funding to accelerate the development and deployment of its automated cell therapy manufacturing platform for advanced therapy medicinal product CDMO clients. - **Q2 2024: Resilience and Takeda Ink Multi-Year Manufacturing Agreement for Cell Therapy Products** Resilience and Takeda signed a multi-year agreement for the manufacturing of cell therapy products, with Resilience providing CDMO services for Takeda’s advanced therapy medicinal product pipeline. ## **Advanced Therapy Medicinal Products CDMO Market Segmentation Insights** ### **Advanced Therapy Medicinal Products CDMO Market Product Type Outlook** - Gene Therapy - Cell Therapy - Tissue Engineering ### **Advanced Therapy Medicinal Products CDMO Market Indication Outlook** - Cancer - Immune Disorders - Cardiovascular Diseases - Neurological Disorders ### **Advanced Therapy Medicinal Products CDMO Market Scale of Production Outlook** - Clinical Trial - Commercial Production ### **Advanced Therapy Medicinal Products CDMO Market Service Type Outlook** - Process Development - Manufacturing - Regulatory Support ### **Advanced Therapy Medicinal Products CDMO Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Africa ## Market Drivers ### Regulatory Support and Frameworks The regulatory landscape surrounding the Advanced Therapy Medicinal Products CDMO Market is evolving, with agencies providing clearer guidelines and support for the development and commercialization of advanced therapies. Regulatory bodies are increasingly recognizing the potential of these therapies, leading to expedited approval processes and incentives for manufacturers. This supportive environment encourages investment in research and development, as companies seek to navigate the complexities of regulatory compliance. The establishment of frameworks that facilitate collaboration between CDMOs and regulatory agencies is likely to enhance the overall efficiency of bringing advanced therapies to market. As a result, the industry is poised for growth, with projections indicating a market expansion to USD 15 billion by 2027. ### Rising Patient Awareness and Acceptance Patient awareness and acceptance of advanced therapies are crucial factors influencing the Advanced Therapy Medicinal Products CDMO Market. As patients become more informed about the benefits of personalized medicine and innovative treatment options, the demand for advanced therapies is likely to increase. Educational initiatives and outreach programs are playing a vital role in enhancing understanding and acceptance among patients and healthcare providers. This growing awareness is expected to drive market growth, as more individuals seek out advanced therapies for conditions that were previously deemed untreatable. The increasing patient advocacy for innovative treatments is likely to create a more favorable landscape for CDMOs, as they align their services with the evolving needs of the healthcare market. ### Growing Investment in Biopharmaceuticals Investment in biopharmaceuticals is a significant driver of the Advanced Therapy Medicinal Products CDMO Market. As pharmaceutical companies increasingly focus on developing biologics and advanced therapies, the demand for specialized manufacturing services is on the rise. Recent reports indicate that biopharmaceutical investments have reached over USD 200 billion, reflecting a robust interest in innovative treatment modalities. This influx of capital is likely to bolster the capabilities of CDMOs, enabling them to expand their service offerings and enhance their technological infrastructure. Consequently, the growth of biopharmaceutical investments is expected to create a favorable environment for CDMOs, facilitating their role in the development and production of advanced therapies. ### Advancements in Manufacturing Technologies Technological advancements play a pivotal role in shaping the Advanced Therapy Medicinal Products CDMO Market. Innovations such as automated bioprocessing, continuous manufacturing, and advanced analytics are revolutionizing the production of advanced therapies. These technologies not only improve efficiency but also enhance product quality and consistency. For instance, the implementation of single-use systems has streamlined operations, reducing contamination risks and lowering costs. As a result, CDMOs are better positioned to meet the increasing demands of the market, which is expected to grow significantly, with estimates suggesting a market size of USD 10 billion by 2025. This technological evolution is essential for maintaining competitiveness in a rapidly evolving landscape. ### Increasing Demand for Cell and Gene Therapies The Advanced Therapy Medicinal Products CDMO Market is experiencing a notable surge in demand for cell and gene therapies. This trend is largely driven by the growing prevalence of chronic diseases and genetic disorders, which necessitate innovative treatment solutions. According to recent data, the market for cell and gene therapies is projected to reach approximately USD 20 billion by 2026, indicating a compound annual growth rate of around 30%. This increasing demand compels CDMOs to enhance their capabilities in manufacturing and development, thereby fostering a more robust ecosystem for advanced therapies. As a result, companies are investing in state-of-the-art facilities and technologies to meet the stringent requirements of these complex products. ## Future Outlook The Advanced Therapy Medicinal Products CDMO Market is projected to grow at a 14.64% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing demand for personalized medicine. **New opportunities:** - Expansion of automated manufacturing processes for efficiency gains. Development of strategic partnerships with biotech firms for innovative therapies. Investment in advanced analytics for predictive quality control in production. By 2035, the market is expected to solidify its position as a leader in biopharmaceutical manufacturing. ## Segment Insights ### By Type: Gene Therapy (Largest) vs. Cell Therapy (Fastest-Growing) In the Advanced Therapy Medicinal Products CDMO Market, the Type segment is marked by the prominent share of Gene Therapy, which stands out as the largest segment. This sector benefits from high investment levels and extensive R&D initiatives aimed at harnessing the potential of genetic material to treat or prevent diseases. In contrast, Cell Therapy is emerging with a rapid growth trajectory, driven by innovative treatment approaches and escalating demand for personalized medicine within the broader advanced therapy medicinal products atmp cdmo market. Gene Therapy (Dominant) vs. Cell Therapy (Emerging) Gene Therapy, recognized as the dominant player in the market, leverages groundbreaking advancements in genetic modification to target and treat various genetic disorders effectively. Its position is fortified by a steady influx of partnerships and collaborations among biotech firms and research institutions. On the other hand, Cell Therapy is marked as an emerging segment, showcasing significant potential, especially in regenerative medicine and immunotherapy, contributing to expanding advanced therapy medicinal products cdmo market share. As it garners increasing attention from stakeholders, this segment is marked by a surge in clinical trials and approvals, demonstrating its transformative capacity in treating chronic conditions and cancers. ### By Indication: Cancer (Largest) vs. Immune Disorders (Fastest-Growing) In the Advanced Therapy Medicinal Products CDMO Market, the indication segment is prominently led by Cancer therapies, which hold the largest market share. This segment's dominance is attributed to the increasing incidence of cancer worldwide and advancements in personalized medicine within the advanced therapy medicinal products cdmo market. Following closely are Immune Disorders, which have gained significant traction due to rising awareness and research in immunotherapies.. The market dynamics indicate that while Cancer treatments continue to be the mainstream focus, Immune Disorders are rapidly catching up, driven by innovations in cellular therapies and gene editing technologies. Indication: Cancer (Dominant) vs. Immune Disorders (Emerging) Cancer therapies, characterized as the dominant force in the Advanced Therapy Medicinal Products CDMO Market, are supported by extensive research and development investments, along with regulatory support that fosters innovation. This area is witnessing robust growth due to effective treatment options such as CAR T-cell therapies and gene therapies, which offer targeted and personalized approaches. On the other hand, Immune Disorders represent an emerging segment, reflecting a paradigm shift towards immunotherapeutics and biologics. With a growing understanding of the immune system's role in various diseases, this segment is poised for accelerated growth, supported by breakthroughs in understanding autoimmune diseases and the development of cutting-edge therapies. ### By Scale of Production: Commercial Production (Largest) vs. Clinical Trial (Fastest-Growing) In the Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) market, the distribution of market share between Clinical Trial and Commercial Production segments reveals a significant dominance of Commercial Production. This segment not only holds the largest share of the market, reflecting the established need for production capabilities at scale, but also showcases the ongoing investments made by CDMOs to enhance their manufacturing processes and infrastructure. On the other hand, the Clinical Trial segment, while smaller in terms of market share, represents a rapidly growing area as more innovative therapies enter the trial phase, highlighting the CDMO's adaptive manufacturing landscape. The growth trends within this segment are notably driven by increasing investments in biopharmaceuticals and gene therapies. As the demand for Advanced Therapy Medicinal Products surges, CDMOs are expanding their service offerings to include tailored solutions for clinical trials, which is the current fastest-growing segment. Factors such as regulatory support for cell and gene therapies and partnerships between biotech firms and CDMOs are propelling this growth, as companies look to efficiently bring their products to market. Clinical trials require specialized production capabilities, which are essential for maintaining compliance and achieving successful outcomes, further underscoring the critical role that CDMOs play in the advancement of these therapies. Production Scale: Commercial Production (Dominant) vs. Clinical Trial (Emerging) The Commercial Production segment in the Advanced Therapy Medicinal Products CDMO market is characterized by its robust infrastructure and established processes, positioning it as the dominant force in this sector. Companies in this segment are equipped with large-scale manufacturing facilities designed to comply with stringent regulatory standards, enabling them to meet the demands of high-volume production. In contrast, the Clinical Trial segment, while emerging, focuses on the unique challenges of producing therapies for research purposes, where flexibility and innovation are paramount. As clinical studies require smaller batches and rapid turnaround times, CDMOs engaged in this area are increasingly adopting agile manufacturing practices. The collaboration between CDMOs and biotechnology firms in clinical settings is fostering advancements in production technology and enhancing process efficiencies. ### By Service Type: Manufacturing (Largest) vs. Process Development (Fastest-Growing) In the Advanced Therapy Medicinal Products Contract Development and Manufacturing Organization (CDMO) Market, the service type segment is primarily dominated by manufacturing, which captures the largest share due to its critical role in the production of advanced therapies. This segment has established itself as the backbone of the industry, providing essential capabilities to ensure the consistent and compliant manufacturing of complex products. Process development follows, coming in as the fastest-growing segment as more organizations recognize the importance of refining and optimizing manufacturing processes to enhance therapeutic outcomes and production efficiency. Manufacturing (Dominant) vs. Process Development (Emerging) The manufacturing segment in the Advanced Therapy Medicinal Products CDMO market is characterized by its extensive capabilities to cater to varied therapeutic modalities, including cell and gene therapies. It serves as a crucial enabler for biopharmaceutical companies, ensuring their products are manufactured at scale while adhering to regulatory standards. Conversely, process development is emerging with a focus on enhancing the manufacturing workflow and optimizing production processes through innovative technologies and methodologies. This segment is rapidly evolving as companies seek to tailor processes that meet specific product requirements, aiming to reduce time-to-market and increase efficiency. ## Regional Market Share Analysis The Advanced Therapy Medicinal Products CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023 and is projected to continue to dominate the market throughout the forecast period. The growth of the North American market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a large number of pharmaceutical and biotechnology companies in the region. Europe is expected to be the second-largest market for advanced therapy medicinal products CDMO in 2023 and is projected to grow at a steady pace during the forecast period. The growth of the European market is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of leading pharmaceutical and biotechnology companies in the region. The APAC market is expected to be the fastest-growing regional market for advanced therapy medicinal products CDMO during the forecast period. The growth of the APAC market is attributed to the increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region. South America and MEA are expected to be relatively smaller markets for advanced therapy medicinal products CDMO but are projected to grow at a steady pace during the forecast period. The growth of these markets is attributed to the increasing healthcare expenditure, the rising demand for innovative therapies, and the presence of a number of emerging pharmaceutical and biotechnology companies in the region. ## Competitive Benchmarking Major players in the advanced therapy medicinal products CDMO market are focusing on developing innovative technologies and expanding their global presence through strategic partnerships and acquisitions. Leading advanced therapy medicinal products CDMO market players are investing heavily in research and development to enhance their product portfolio and gain a competitive edge. The advanced therapy medicinal products CDMO market development is driven by rising demand for personalized medicine and increasing government support for regenerative therapies. The competitive landscape is expected to remain fragmented, with several key players holding significant market share. Lonza is a leading provider of Advanced Therapy Medicinal Products CDMO Market services, offering a comprehensive range of solutions for cell and gene therapies, including cell culture media, bioprocess development, and manufacturing. The company has a strong global presence with facilities in Europe, North America, and Asia. Lonza's commitment to innovation and customer service has earned it a reputation as a trusted partner for biotechnology and pharmaceutical companies. Samsung Biologics is another major player in the advanced therapy medicinal products CDMO market. The company offers a full suite of services for cell and [gene therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) development and manufacturing, including cell line development, process optimization, and GMP manufacturing. Samsung Biologics has a state-of-the-art manufacturing facility in South Korea and is expanding its global presence through partnerships with leading biotechnology companies. ## Recent News & Developments - **Q2 2024: Catalent opens new cell therapy manufacturing facility in Belgium** Catalent announced the opening of a new commercial-scale cell therapy manufacturing facility in Gosselies, Belgium, expanding its advanced therapy medicinal product (ATMP) CDMO capabilities in Europe. - **Q2 2024: Charles River Laboratories and Cellarity Announce Strategic Partnership to Advance Cell Therapy Manufacturing** Charles River Laboratories and Cellarity entered a strategic partnership to accelerate the development and manufacturing of cell therapies, leveraging Charles River’s CDMO expertise for advanced therapy medicinal products. - **Q2 2024: WuXi Advanced Therapies Expands Philadelphia Facility to Boost Cell and Gene Therapy Manufacturing** WuXi Advanced Therapies completed a major expansion of its Philadelphia facility, increasing capacity for cell and gene therapy manufacturing services as a CDMO for advanced therapy medicinal products. - **Q2 2024: Minaris Regenerative Medicine Announces New Commercial Manufacturing Agreement with Autolus Therapeutics** Minaris Regenerative Medicine signed a commercial manufacturing agreement with Autolus Therapeutics to provide CDMO services for the production of Autolus’ advanced cell therapy products. - **Q1 2024: Lonza Expands Cell and Gene Therapy Manufacturing Capabilities with New Suite in Houston** Lonza announced the opening of a new manufacturing suite at its Houston facility, enhancing its capacity to deliver CDMO services for advanced therapy medicinal products. - **Q1 2024: Samsung Biologics to Acquire Stake in Gene Therapy CDMO Senda Biosciences** Samsung Biologics agreed to acquire a minority stake in Senda Biosciences, a CDMO specializing in gene therapy, to expand its advanced therapy medicinal product service portfolio. - **Q2 2024: Thermo Fisher Scientific Launches New Plasmid DNA Manufacturing Facility in California** Thermo Fisher Scientific opened a new plasmid DNA manufacturing facility in Carlsbad, California, to support the growing demand for CDMO services in the advanced therapy medicinal products sector. - **Q2 2024: AGC Biologics Announces Partnership with Adaptimmune for Cell Therapy Manufacturing** AGC Biologics entered a partnership with Adaptimmune to provide contract manufacturing services for Adaptimmune’s cell therapy pipeline, expanding AGC’s advanced therapy medicinal product CDMO offerings. - **Q1 2024: CellPoint and Lonza Enter Manufacturing Collaboration for Point-of-Care CAR-T Therapies** CellPoint and Lonza announced a collaboration to develop and manufacture point-of-care CAR-T cell therapies, leveraging Lonza’s CDMO expertise in advanced therapy medicinal products. - **Q2 2024: VIVEbiotech Expands Lentiviral Vector Manufacturing Facility in Spain** VIVEbiotech completed an expansion of its lentiviral vector manufacturing facility in San Sebastián, Spain, to meet increased demand for CDMO services in the advanced therapy medicinal products market. - **Q1 2024: Cellares Raises $255 Million Series C to Scale Automated Cell Therapy Manufacturing** Cellares secured $255 million in Series C funding to accelerate the development and deployment of its automated cell therapy manufacturing platform for advanced therapy medicinal product CDMO clients. - **Q2 2024: Resilience and Takeda Ink Multi-Year Manufacturing Agreement for Cell Therapy Products** Resilience and Takeda signed a multi-year agreement for the manufacturing of cell therapy products, with Resilience providing CDMO services for Takeda’s advanced therapy medicinal product pipeline. ## Report Scope | MARKET SIZE 2024 | 29.97(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 34.36(USD Billion) | | MARKET SIZE 2035 | 134.73(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 14.64% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Lonza (CH), Catalent (US), Samsung Biologics (KR), WuXi AppTec (CN), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), AptarGroup (US), Novartis (CH), Thermo Fisher Scientific (US) | | Segments Covered | Product Type, Indication, Scale of Production, Service Type, Regional | | Key Market Opportunities | Growing demand for personalized medicine drives innovation in Advanced Therapy Medicinal Products CDMO Market. | | Key Market Dynamics | Rising demand for personalized medicine drives competition among Advanced Therapy Medicinal Products Contract Development and Manufacturing Organizations. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Advanced Therapy Medicinal Products CDMO Market?** A: The market valuation was 29.97 USD Billion in 2024. **Q: What is the projected market size for the Advanced Therapy Medicinal Products CDMO Market by 2035?** A: The market is expected to reach 134.73 USD Billion by 2035. **Q: What is the expected CAGR for the Advanced Therapy Medicinal Products CDMO Market during the forecast period 2025 - 2035?** A: The expected CAGR is 14.64% during the forecast period. **Q: Which companies are considered key players in the Advanced Therapy Medicinal Products CDMO Market?** A: Key players include Lonza, Catalent, Samsung Biologics, WuXi AppTec, and Boehringer Ingelheim. **Q: What are the main segments of the Advanced Therapy Medicinal Products CDMO Market?** A: The main segments include Gene Therapy, Cell Therapy, and Tissue Engineering. **Q: How does the market perform in terms of indication segments?** A: The market shows notable performance in Cancer, Immune Disorders, Cardiovascular Diseases, and Neurological Disorders. **Q: What is the scale of production in the Advanced Therapy Medicinal Products CDMO Market?** A: The scale of production includes Clinical Trials and Commercial Production, with the latter valued at 19.97 USD Billion in 2024. **Q: What types of services are offered in the Advanced Therapy Medicinal Products CDMO Market?** A: Services include Process Development, Manufacturing, and Regulatory Support. **Q: What was the valuation of the Cell Therapy segment in 2024?** A: The Cell Therapy segment was valued at 10.0 USD Billion in 2024. **Q: What is the projected growth for the Gene Therapy segment by 2035?** A: The Gene Therapy segment is projected to grow to 40.0 USD Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/advanced-therapy-medicinal-products-cdmo-market-31150*